Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Magle Biopharma AB
AB
Active
Org 5566560156
Sheelevägen 2, 223 63
Lund
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2004 · 22 years old
1-4 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Magle Biopharma AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
0M
0M
-1M
-1M
2020: 0M
0M
2020
2021: 0M
0M
2021
2022: 0M
0M
2022
2023: 0M
0M
2023
2024: 0M
0M
2024
EBITDA
SEK millions
0M
-2M
-3M
-5M
-6M
2020: 0M
0M
2020
2021: -1M
-1M
2021
2022: 0M (+100% vs 2021)
0M
2022
2023: 0M
0M
2023
2024: -5M
-5M
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
0
0
0
0
0
Staff expenses
—
—
—
—
—
EBITDA
−4 610
0
−91
−787
−484
Depreciation & amort.
−337
—
−0
−22
−65
EBIT
−4 947
0
−91
−809
−549
Net financials
−6
2
—
—
—
Profit before tax
2
2
1
−1
0
Tax
−0
—
−0
−0
−0
Net profit
2
2
1
−1
0
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
46 235
925
923
922
958
Equity
927
925
923
922
923
Long-term debt
0
—
0
0
0
Short-term debt
45 309
0
0
0
36
Total debt
45 309
0
—
—
36
Financial ratios
5-year trend
EBITDA margin
<−999 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2020
2024
Equity ratio
2,0 %
This company
38,2 %
Market median
This company
Market median
95% below market
2020
2024
Return on equity
0,2 %
This company
18,4 %
Market median
This company
Market median
99% below market
2020
2024
Net profit margin
>999 %
This company
8,1 %
Market median
This company
Market median
>999% above market
2020
2024
Asset turnover
0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2020
2024
Debt / equity
48,88×
This company
0,62×
Market median
This company
Market median
>999% above market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on Magle Biopharma AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
